Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Celltrion and Teva Sign $160 Million Pact to Market Biosimilars in US

publication date: Oct 6, 2016

Celltrion of South Korea engaged Teva to commercialize two of its biosimilar cancer drugs in the US and Canada. Teva paid $160 million upfront, though $60 million could be returned under certain (undisclosed) conditions. The two products have major potential markets because they are versions of Rituxan® and Herceptin®, two very important Roche/Genentech cancer treatments. Celltrion will be responsible for clinical tests and regulatory submissions, while it will share in the profits with Teva. Rituxan loses its US patent protection in 2018 and Herceptin in 2019. As patent-protected medications, the two drugs currently produce revenues of $6.5 billion in the US and Canada. More details....

Stock Symbols: (KOSDAQ: 068270) (NYSE/TASE: TEVA) (SIX: ROG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital